AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0081
Drug name and formulations:	Palexia SR® (Tapentadol prolonged-release tablets)

Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	Some circumstantial evidence presented suggesting there may be a lower risk of abuse.
Clinical effectiveness	*Established licensed product*	As effective as oxycodone.
Strength of evidence		Reliance on case studies/anecdotal. No additional evidence supplied.
Cost effectiveness or resource impact	*£*	Figures cited in application state 50mg tapentadol SR equivalent to 10mg oxycodone MR. Literature states 10mg oxycodone is equivalent to 50-75mg tapentadol. Tapentadol therefore more costly than oxycodone.
Place of therapy relative to available treatments	*1/2nd tier*	3rd/4th tier.
National guidance and priorities	*NICE, MTRAC*	SMC approved. Not reviewed by NICE.
Local health priorities	*CCG views*	Concern regarding opioid over prescribing.
Equity of access	*Equality assessment*	Committee acknowledges that surrounding areas have differing formulary status' for Palexia SR®.
Stakeholder views	*Define wider groups to be engaged*	N/A

Implementation requirements	*Requires, RICAD ESCA etc.*	N/A

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	Invite a resubmission of the application with additional evidence.
Not approved and rationale:	
Formulary status (RAG) and rationale	Remain as RED. Rationale: No additional evidence presented. Applicant invited to submit a full application.
Implementation requirements:	
Implementation monitoring:	